[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 368
Citations 0
News From the Food and Drug Administration
December 15, 2015

Two Melanoma Drugs Better Than 1

JAMA. 2015;314(23):2497. doi:10.1001/jama.2015.16798

Cobimetinib, which inhibits an enzyme known as MEK, has received approval to treat melanoma that has metastasized or can’t be surgically removed. The drug, marketed as Cotellic, is to be used in combination with vemurafenib (http://1.usa.gov/1RLrgf4).

Together, both drugs target melanoma tumors with BRAF V600E or V600K mutations. Found in about half of melanomas, mutated BRAF causes abnormal signaling in cancer cells, leading to tumor growth (http://bit.ly/1ML7H26). While vemurafenib inhibits some mutated forms of BRAF, cobimetinib blocks some forms of MEK, which is part of the same cell signaling pathway.

First Page Preview View Large
First page PDF preview
First page PDF preview